AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03522337 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional leaflets
Description: Oral health instruction, tooth-brushing training (toothbrushes and fluoridated toothpastes provided)
Study NCT03634345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2: Cohort 2: Fluconazole & PF-04965842
Description: Cohort 2: Period 2: Administration of fluconazole from Day 1 to Day 7 and PF-04965842 on Day 5.
Study NCT03744078 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley balloon catheter
Description: 18-F Foley catheter which filling with 60 mL of saline solution will be placed into the cervix
Study NCT03459352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ePRO
Description: Patients will be instructed to log symptoms with an ePRO app using their own personal devices, and prompted once per month for 12 months to log symptoms.~These participants will be sent an Adverse Event Questionnaire (AEQ) via the Noona tool that summarizes their symptoms and distress once per month and one week prior to any medically indicated oncology clinic visit.~Symptoms designated as clinically severe either during regular symptom logging or via the AEQ will trigger a prompt to contact the clinical team for immediate follow-up. Participants will complete a follow-up questionnaire at 6 months and 12 months following enrollment that includes a self-report of symptom burden, HRQOL, and satisfaction.
Study NCT02049021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MECTA SPECTRUM 5000Q ECT
Study NCT02049021 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham ECT
Description: Sedation using propofol or etomidate and usual ECT preparation (no stimulation)
Study NCT02794935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Description: Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 30% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 minutes for 12 weeks. During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min. Inspiratory load will be set at 30% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 30% of MIP. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
Study NCT02794935 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham IMT
Description: Participants will be submitted to inspiratory muscle training with the same equipment as the intervention group, but without a load generating resistance. Sham IMT Participants will receive IMT for 30 min, 7 times per week for 12 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance. Each week, six training sessions will be held at home and a training session will be supervised in the research center
Study NCT01733147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 polyunsaturated fatty acids
Description: 3 capsules a day of Omega 3 polyunsaturated fatty acids taken orally for six months; 2 capsules with breakfast and 1 capsule with their evening meal. Active drug will consist of 1200 mg of a ω3 FFA preparation containing 675 mg EPA and 300 mg DHA.
Study NCT01733147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 capsules a day of placebo (1200 mg of ethyl oleate 3 capsules a day) taken orally for six months; 2 capsules with breakfast and 1 capsule with their evening meal.
Study NCT00841360 — intervention group
Intervention type: OTHER
Intervention: Index Recruiter
Description: Participants agree to recruit at least two female friends from their friendship network to undergo HIV screening.
Study NCT00841360 — intervention group
Intervention type: OTHER
Intervention: Friendship Network Member
Description: Participants are recruited by Index Recruiters to enroll in study and receive HIV screening and complete a questionnaire either on Facilitators of HIV Screening or Barriers to HIV Screening.
Study NCT04107142 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell
Description: Adoptive Cell Transfer of Haploidentical / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells (CTM-N2D)
Study NCT05797584 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dobutamine
Description: Dobutamine 5.0 - 10.0 mcg/Kg/min ev
Study NCT05797584 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Passive leg raising
Description: Passive leg raising for acute volume load
Study NCT03922074 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sedation directed by an endoscopist
Description: The nurse begins with fentanyl infusion in bolus: 75 μg (1.5 ml) and initial propofol dose (10mg/ml) in bolus of 0.5 - 2.5 mg/Kg followed by a maintenance dose of 20 - 60ml/h through Target-controlled infusion (TCI) pump. In this way, we get a target level sedation between 1 - 3, according to Observer's Assessment of Alertness/Sedation Scale (OAAS).~The role of the nurse, directed by an endoscopist, it is exclusively the administration of intravenous drugs and the patient monitorship throughout the procedure.
Study NCT03922074 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sedation directed by an anesthesiologist
Description: The choice of the drugs and the target level sedation are directed by an anesthesiologist
Study NCT01360866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712
Description: Tablet
Study NCT01360866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Tablet
Study NCT01360866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Capsule
Study NCT01360866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine CR
Description: Controlled-release tablets
Study NCT01360866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Tablets
Study NCT01360866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Delayed-release capsules
Study NCT01360866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR
Description: Extended-release capsules
Study NCT03380390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline HCL 1.0% Cream
Description: Oxymetazoline HCl cream 1.0% once daily application
Study NCT03380390 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Energy-Based Therapy
Description: Energy-based therapies (Potassium Titanyl Phosphate \[KTP\], Pulsed Dye Laser \[PDL\], or Intense Pulsed Light \[IPL\])
Study NCT03615495 — intervention group
Intervention type: DEVICE
Intervention: Flourish Pediatric Esphogeal Atresia device
Description: The Flourish Pediatric Esophageal Atresia device consists of an esophageal catheter and a gastric catheter. Both catheters are equipped with an inner magnet catheter. When the esophageal and gastric catheters are aligned tip to tip, the magnets attract.
Study NCT00870207 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tu Salud Si Cuenta Worksite Intervention
Description: The intervention will consist of providing TSSC newsletters to employees of the worksite. Additionally, informational sessions about physical activity and healthful food choice (consistent with the TSSC messages) during work hours will be implemented. Social support groups for the behavior changes will be established thru colleague networks. Individualized behavior change plans will be designed for enrolled participants. Additionally, environmental changes including a well equipped exercise facility on site and access to healthful foods in vending machines and work groups providing fruit and vegetable access in kitchen area will be implemented.
Study NCT03393078 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation with real coil
Description: TMS with real coil is a noninvasive technique to activate and modify the activity of the neurons
Study NCT03393078 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial magnetic stimulation with sham coil
Description: TMS with sham coil is a placebo
Study NCT02951013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: restrictive transfusion
Description: Transfusion will start when the hemoglobin concentration falls below 6.0 g/dL
Study NCT02951013 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: liberal transfusion
Study NCT01243619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3'-deoxy-3'-(18) F-fluorothymidine
Description: Radio-tracer for tumor imaging
Study NCT03529396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Standard chloroquine (three days)
Study NCT03529396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Standard chloroquine (three days)
Study NCT03529396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Daily Primaquine (0.5 mg of base/kg/day for seven days) starting only at the fifth day post chloroquine initiation.
Study NCT03529396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: Weekly primaquine (0.75 mg of base/kg/week for eight weeks) starting with first dose of chloroquine.
Study NCT03529396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Weekly, once a week chloroquine (5 mg of base/kg/week for twelve weeks)
Study NCT03529396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: Standard primaquine (0.5mg of base/kg/day for seven days) concomitant with chloroquine.
Study NCT01684397 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT03475368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carbs diet
Description: People randomized to this interventional group will take low carbs diet (i.e. with a limited amount of carbohydrates)
Study NCT03475368 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet
Description: People randomized to this interventional group will take a traditional Mediterranean diet.
Study NCT01684397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01684397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO
Study NCT01684397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00828932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin
Study NCT02671305 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: placental circulation intact
Description: bedside assistance with placental circulation intact during first 3 minutes of life
Study NCT02671305 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cord milking
Description: neonatal assistance in a standard setting after cord milking (milking four times 20 cm of cord)
Study NCT02040493 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intra-operative radiation therapy (IORT)
Description: All subjects will receive IORT at the time of lumpectomy.
Study NCT02200432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PERSPeCT Recommender System
Description: PERSPeCT will use data to predict messages that would be most influential to the participant in health behavioral change.~Patient Experience Recommender System for Persuasive Communication Tailoring. PERSPeCT is an adaptive computer system that will assess a patient's individual perspective, understand the patient's preferences for health messages, and provide personalized, persuasive health communication relevant to the individual patient.
Study NCT02415439 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00904540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidoderm®
Description: Patients participated in a 6-week treatment period. Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain. Patients were stratified into the following groups at enrollment: acute (\<6 weeks) LBP, subacute (6 weeks to \<3 months) LBP, short-term chronic (3 months to 12 months, inclusive) LBP, and long-term chronic (>12 months LBP)
Study NCT01604304 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: flexible ureteroscopy
Description: Flexible ureteroscopy will be use for 120 min max to treat renal stone. Laser, access sheath, baskets can be use to perform the technique.
Study NCT00550524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplantation
Description: Autologous bone marrow aspiration (20 ml) from iliac crest. Separation of mononuclear cells using ficoll hypaque and culture in 10% fetal bovine serum and Dulbecco modified eagles medium. After confluent stage, detachment of cells with trypsin/EDTA, and subculture. Repeated passages until obtainment of required cell number. Confluent cells of last passage are washed with tyrode solution and incubate with M199 for 60 minutes. Cells are separated using trypsin/EDTA and washed 3 times with M199 and 1% HSA. Precipitate will be diluted with heparinized M199 to make solution with 6×106 cells /ml. Sample will be tested for viability and detection of CD45, CD34, CD90, CD44, CD13, CD105, and CD166 before injection. The number of cells for injection will be between 20-25 million cells; in a maximum volume of 4-6 ml. Cells will be injected in the knee joint with a 21 gauge needle.
Study NCT01935791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Vehicle
Description: Temperature
Study NCT01935791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 1 Visit 1 - Cold PET-CT Vehicle, Visit 2 -Warm PET-CT Glucagon
Description: Hormone
Study NCT01935791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Period 1 Visit 1 - Cold PET-CT Vehicle, no visit 2 as BAT negative
Description: Temperature
Study NCT01935791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2 - Visit 1 Warm Control vehicle, Visit 2 Warm Glucagon, Visit 3 Cold control
Description: Hormone
Study NCT01935791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2 - Visit 1 Warm Glucagon, Visit 2 Cold control , Visit 3 Warm control
Description: Hormone
Study NCT01935791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2 -Visit 1 cold control, Visit 2 warm control, Visit 3 Warm glucagon
Description: hormone
Study NCT01604304 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: extracorporeal shockwave lithotripsy
Description: The lithotriptor is use with 1,1 Hz frequency and stop when patient get 1000 joules of energy or if there is a problem with tolerance of this treatment or if stone is broken
Study NCT00200252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin
Study NCT03480607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine group
Description: 0.75 ml of 0.5% Bupivacaine in conjunction with 0.5 mcg/kg dexmedetomidine
Study NCT03480607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone group
Description: 0.75 ml of 0.5% Bupivacaine in conjunction with 0.1 mcg/kg dexamethasone
Study NCT03164226 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Digital plethysmography in stratifying the cardiovascular risk for patients consulting for chest pain
Description: To verify the contribution of digital plethysmography in stratifying the cardiovascular risk for patients consulting for chest pain
Study NCT01935791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2 -Visit 1 cold control, visit 2 warm glucagon, visit 3 warm control
Description: hormone
Study NCT01935791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2- Visit 1 Warm glucagon, visit 2 warm control, visit 3 cold control
Description: hormone
Study NCT01935791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2 - Visit 1 Warm control, visit 2 cold control, visit 3 warm glucagon
Description: Hormone
Study NCT03513328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa--single daily dose
Description: Conditioning regimen for hematopoietic stem-cell transplant. Single daily IV dose of Thiotepa at 5 mg/kg.
Study NCT03513328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiotepa--single daily dose
Description: Conditioning regimen for hematopoietic stem-cell transplant. Single daily IV dose of Thiotepa at 5 mg/kg.
Study NCT03513328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa--escalated dose
Description: Twice daily IV dose of Thiotepa at 5 mg/kg, twelve hours apart, 10mg/kg total.
Study NCT03513328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiotepa--escalated dose
Description: Twice daily IV dose of Thiotepa at 5 mg/kg, twelve hours apart, 10mg/kg total.
Study NCT01924000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minoxidil lotion 1%
Description: Minoxidil lotion 1% is applied twice daily to one eyebrow.
Study NCT01924000 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04692025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC41 tablet
Description: Oral tablet
Study NCT02538081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone plus Placebo
Description: Standard of care including Risperidone plus Placebo
Study NCT02538081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone plus DMXB-A
Description: Standard of care including Risperidone plus DMXB-A
Study NCT01458236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beraprost Sodium 314d Modified Release Tablets
Description: Available as 15 μg and 60 μg tablets for oral, twice daily (BID) administration
Study NCT01458236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR and are for oral, BID administration, will be utilized in subjects assigned to the placebo study drug treatment group
Study NCT02398578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amphora OAB Device
Description: Cystoscopic procedure to treat OAB
Study NCT01805804 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo/valsartan
Study NCT01805804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo/valsartan
Study NCT00804284 — intervention group
Intervention type: BIOLOGICAL
Intervention: DTaP-IPV/Hib
Description: 0.5 mL, Intramuscular
Study NCT00804284 — intervention group
Intervention type: BIOLOGICAL
Intervention: Other DTap Vaccines
Description: 0.5 mL, Intramuscular
Study NCT02737696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based prescription opioid prevention for adolescents
Description: The intervention focuses on individual skills factors (e.g., promoting accurate knowledge about risks), as well as peer and societal influences on prescription opioid abuse (e.g., training skills to refuse offers to misuse opioids). When accessing the program, users see pictures of youth who have been in treatment for opioid dependence, and may choose to click on links to: 1) listen to or read real stories of problematic involvement with prescription opioids, 2) view youth' trajectories of important decision points related to prescription opioid misuse, 3) view videos that provide key information or teaches a skill that might help a young person make healthier choices (e.g., refusing offers to misuse prescription opioids), 4) or take quizzes to assess information/skill acquisition.
Study NCT02737696 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: JustThinkTwice.gov website (DEA)
Description: The JustThinkTwice.com website is educational (a large percentage of the website content focuses on opioids) with a menu including: Drug Information, True Stories (of youth who have lost their lives to drugs), Consequences, Facts/Statistics, Videos (e.g., the Life of an Opiate Addict, and Synthetic Drugs), and a brief Quiz.
Study NCT04584450 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: data collection using questionnaire
Study NCT04169399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 240mg intravenously every 3 weeks
Study NCT04169399 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: Radiotherapy dose was 36 \~ 54Gy, divided into 6 times of irradiation, and the radiation was performed within 2 weeks.
Study NCT01834703 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: UAE
Description: The patient will be admitted into hospital for UAE. UAE was performed with patients under local anesthesia. Embosphere particles (BioSphere Medical) with a size of 500 - 700µm were used in all procedures. Embospheres were mixed with contrast material and saline and injected into each uterine artery until either parenchyma filling of the fibroids had stopped (target embolization) or the main uterine artery was blocked with stasis of contrast material (selective embolization). After the procedure, women were admitted to the gynecology ward for postprocedural care. All patients were advised to stay in the hospital for at least 1 night.